Posted by Michael Wonder on 30 Jun 2021
Cend Therapeutics’ CEND-1 granted fast track designation for pancreatic cancer
29 June 2021 - The US FDA has granted fast track development status for Cend’s investigational drug, CEND-1, for the first-line treatment of metastatic pancreatic ductal adenocarcinoma in combination with gemcitabine/nab-paclitaxel.
In addition, following encouraging Phase 1b/2 clinical trial results, Cend and collaborators are initiating a controlled Phase 2b clinical trial in mPDAC.
CEND-1 was granted orphan drug designation by the FDA for the treatment of pancreatic cancer in January 2019.
